CSIMarket
 
Aeon Biopharma inc   (NYSEAMER: AEON)
Other Ticker:  
 
 
Price: $0.1205 $0.00 -3.754%
Day's High: $0.1252 Week Perf: -0.82 %
Day's Low: $ 0.12 30 Day Perf: -78.82 %
Volume (M): 1,876 52 Wk High: $ 17.17
Volume (M$): $ 226 52 Wk Avg: $3.01
Open: $0.13 52 Wk Low: $0.10



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 37
 Employees 11
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -293
 Cash Flow (TTM) (Millions $) -31
 Capital Exp. (TTM) (Millions $) 0

Aeon Biopharma Inc
Aeon Biopharma Inc is a biopharmaceutical company that specializes in developing and commercializing innovative therapies for various diseases. They focus on advancing the treatment options available to patients and improving their quality of life. Aeon Biopharma Inc conducts research, clinical trials, and manufacturing of its pharmaceutical products. They strive to bring new and effective treatments to the market by leveraging cutting-edge technologies and collaborations with industry experts. Their mission is to address unmet medical needs and make a positive impact on the health and well-being of patients worldwide.


   Company Address: 5 Park Plaza Irvine 92614 CA
   Company Phone Number: 354-6499   Stock Exchange / Ticker: NYSEAMER AEON


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        4.91% 
BHC   -1.61%    
BMRN        0.48% 
JAZZ   -3.61%    
LLY        7.39% 
VRTX        5.21% 
• View Complete Report
   



Shares

AEON Biopharma Navigates Regulatory Gains and Clinical Trials as It Launches Public Offering,

Published Sat, Jan 4 2025 1:02 AM UTC

AEON Biopharma, Inc. Launches Proposed Public Offering Amid FDA Progress and Market Challenges IRVINE, Calif., Jan. 03, 2025 AEON Biopharma, Inc. (NYSE: AEON), a clinical-stage biopharmaceutical company dedicated to advancing a botulinum toxin complex through the 351(k) biosimilar pathway, has officially announced the commencement of a public offering. This strategic mov...

Clinical Study

AEON Biopharma Gains FDA Alignment on ABP-450 Biosimilar Pathway Amid Mixed Clinical Results, Showcases Si...

Published Mon, Sep 30 2024 12:01 PM UTC

AEON Biopharma Advances Regulatory Pathway for ABP-450 and Showcases Pivotal Clinic...

Stocks on the Move

AEON Biopharmas Focus Realigns Towards Biosimilar Pathway for ABP-450 A Shift in Strategy

Published Wed, Jul 17 2024 9:14 PM UTC

In recent news, AEON Biopharma, a prominent pharmaceutical company, announced a strategic reprioritization to pursue a biosimilar pathway for ABP-450. This shift in focus has come after the preliminary results of AEON Biopharma s Phase 2 trial for chronic migraine treatment failed to show significant improvement over a placebo. At the same time, AEON Biopharma s shares have...

Stocks on the Move

Analyzing the Recent Sell-off in Aeon Biopharma Inc Shares Factors Impacting Performance

Published Tue, Jul 16 2024 9:39 AM UTC

Aeon Biopharma Inc, a clinical-stage biopharmaceutical company focused on the development of a botulinum toxin complex for multiple therapeutic indications, has experienced a significant sell-off in its shares recently. This article aims to explore the underlying factors behind this decline, particularly by examining recent events and financial performance.Event 1: Sunshine ...

Clinical Study

AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450

Published Tue, Jul 9 2024 12:01 PM UTC

AEON Biopharma Shifts Strategic Focus: Pioneers Biosimilar Pathway for ABP-450 with Proactive Phase 3 Trials and Promising Results AbstractAEON Biopharma is set to recalibrate its strategic direction toward developing biosimilars with a focused effort on ABP-450 through a 351(k) pathway. Scheduled to initiate a head-to-head comparative Phase 3 study with BOTOX? for cervical...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com